Prednisolone clinical trials
Prednisolone is named as an intervention in 73 current clinical trials in our Canada, Australia, Israel, USA, Germany, Italy, France, China, Spain, Japan, Mexico, Poland, South Korea, Netherlands, Switzerland, Austria, Taiwan, UK, Denmark, Belgium, Sweden, Turkey, Czechia, Brazil, Singapore, Portugal, Ireland, Egypt, Norway and India registers. 42 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (7). The most-studied condition is Prostate Cancer. The EU clinical trials register (CTIS) separately lists 4 authorised or ongoing trials, 1 with a site in Ireland.
Where Prednisolone is approved
All regulators →Of the three regulators tracked here, the first to approve Prednisolone was the US, on 22 May 1955. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Prednisolone
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Prednisolone works
All drug targets →- Glucocorticoid receptor agonist AgonistTarget: NR3C1 nuclear receptor subfamily 3 group C member 1✓ In ChEMBL and the Guide to Pharmacology
- PainPhase 3
- SciaticaPhase 3
- Anterior uveitisPhase 3
- Atopic eczemaPhase 3
- CataractPhase 3
- Contact dermatitisPhase 3
- PsoriasisPhase 3
- Seborrheic dermatitisPhase 3
- Cystoid macular edemaPhase 2/3
- Macular retinal edemaPhase 2/3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1152, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 2866, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Prednisolone
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 10 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Prednisolone
- ChEMBL
- CHEMBL1152
- DrugBank
- DB15566
- PubChem CID
- 5834
- CAS number
- 52-21-1
- FDA UNII
- 8B2807733D
- Wikidata
- Q27108063
- Wikipedia
- Prednisolone acetate
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Prednisolone
73 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Prednisolone in the EU trials register (CTIS)
4 trials · 1 in IrelandAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Prednisolone. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
Prednisolone across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
10 single-substance products containing Prednisolone on the HPRA medicines list.
- DELTACORTRIL ENTERIC 2.5 mg gastro-resistant tabletsPhoenix Labs · PA1113/003/002 · Marketed
- DELTACORTRIL ENTERIC 5 mg gastro-resistant tabletsPhoenix Labs · PA1113/003/001 · Marketed
- Minims Prednisolone Sodium Phosphate 0.5% w/v Eye Drops, SolutionBausch + Lomb Ireland Limited · PA23259/019/001 · Marketed
- Pred Forte 1% w/v, Eye Drops SuspensionAbbVie Limited · PA1824/010/001 · Marketed
- Prednesol 5mg TabletsPhoenix Labs · PA1113/001/001 · Marketed
Supply shortages
- Predni-POS 1 %Germany (BfArM) · Production problem · 21 Nov 2024 to 31 Dec 2026
- Predni-POS 0,5%Germany (BfArM) · Production problem · 3 Feb 2026 to 31 Dec 2026
- Dontisolon D MundheilpasteGermany (BfArM) · Production problem · 1 Jun 2026 to 1 Mar 2027
- Dontisolon D MundheilpasteGermany (BfArM) · Production problem · 1 Jun 2026 to 1 Mar 2027
- Dontisolon D ZylinderampullenGermany (BfArM) · Production problem · 1 Jul 2026 to 1 Mar 2027
Conditions studied with Prednisolone
124 conditionsAll 124 conditions
| Condition (as registered) | Trials |
|---|---|
| Prostate Cancer | 4 |
| Acute Lymphoblastic Leukemia | 4 |
| B Acute Lymphoblastic Leukemia | 4 |
| Down Syndrome | 3 |
| Chronic Graft-versus-host-disease | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Prostatic Neoplasms | 2 |
| Follicular Lymphoma | 2 |
| Allergic Bronchopulmonary Aspergillosis | 2 |
| Sarcoidosis | 2 |
| Mixed Phenotype Acute Leukemia | 2 |
| Lymphoma | 2 |
| B Lymphoblastic Lymphoma | 2 |
| Lymphoblastic Lymphoma, Childhood | 1 |
| Neoplasm Metastasis | 1 |
| Urogenital Neoplasms | 1 |
| Physiological Effects of Drugs | 1 |
| Metastatic Castration-Resistant Prostate Cancer | 1 |
| Metastatic Hormone Sensitive Prostate Cancer | 1 |
| Solid Tumor | 1 |
| Chronic Graft Versus Host Disease | 1 |
| Endometrial Cancer | 1 |
| Gastric Cancer | 1 |
| Metastatic Castration-resistant Prostate Cancer | 1 |
| Ovarian Cancer | 1 |
| X-Linked Myotubular Myopathy | 1 |
| Pyoderma Gangrenosum | 1 |
| OTC Deficiency | 1 |
| Lymphoma, B-Cell | 1 |
| Prostate Cancer Metastatic | 1 |
| Leber Congenital Amaurosis | 1 |
| LCA | 1 |
| LCA1 | 1 |
| Diffuse Large B-Cell Lymphoma | 1 |
| Hypersensitivity Pneumonitis | 1 |
| Diffuse Large B-cell Lymphoma | 1 |
| Diffuse Large B-Cell Lymphoma (DLBCL) | 1 |
| IgA Nephropathy (IgAN) | 1 |
| Abiraterone Acetate | 1 |
| MCRPC (metastatic Castration-resistant Prostate Cancer) | 1 |
| Takayasu Arteritis (TAK) | 1 |
| Glomerulonephritis, IGA | 1 |
| Neoadjuvant Therapy | 1 |
| High Risk Prostate Cancer | 1 |
| Locally Advanced Prostate Cancer | 1 |
| Intense Endocrine Therapy | 1 |
| Crohn Disease | 1 |
| Nutrition Assessment | 1 |
| Diet Therapy | 1 |
| Paediatric Stroke | 1 |
| Mature B-cell Non-Hodgkin Lymphoma | 1 |
| COVID-19 Associated Cardiac Involvement | 1 |
| Remodeling, Left Ventricle | 1 |
| Remodeling, Vascular | 1 |
| Left Ventricular Dysfunction | 1 |
| T Acute Lymphoblastic Leukemia | 1 |
| Acute Lymphoblastic Leukemia, Pediatric | 1 |
| DLBCL | 1 |
| Alcoholic Hepatitis | 1 |
| Radionecrosis of Brain | 1 |
| Brain Metastases | 1 |
| Lymphoma, Large B-Cell, Diffuse (DLBCL) | 1 |
| Glomerulonephritis | 1 |
| Immunoglobulin A Nephropathy | 1 |
| Metastatic Cancer | 1 |
| Castrate Sensitive Prostate Cancer | 1 |
| Recurrent Miscarriage | 1 |
| Recurrent Pregnancy Loss | 1 |
| Habitual Abortion | 1 |
| Miscarriage | 1 |
| Lupus Nephritis | 1 |
| Systemic Lupus Erythematosus (SLE) | 1 |
| DLBCL - Diffuse Large B Cell Lymphoma | 1 |
| Asthma | 1 |
| COPD | 1 |
| Colitis | 1 |
| Acute Tubulo-Interstitial Nephritis | 1 |
| Anaphylactic Reaction | 1 |
| Anaphylaxis | 1 |
| Allergy in Children | 1 |
| IgE Mediated Food Allergy | 1 |
| Primary Mediastinal Large B-Cell Lymphoma | 1 |
| Central Nervous System Leukemia | 1 |
| Neoplasms, Prostate | 1 |
| Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | 1 |
| Recurrent Acute Leukemia of Ambiguous Lineage | 1 |
| Recurrent Acute Lymphoblastic Leukemia | 1 |
| Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage | 1 |
| Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged | 1 |
| Cardiac Sarcoidosis | 1 |
| Nephrotic Syndrome in Children | 1 |
| Nephrotic Syndrome, Minimal Change | 1 |
| Nephrotic Syndrome | 1 |
| Nephrotic Syndrome，Idiopathic | 1 |
| Childhood Cancer | 1 |
| Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | 1 |
| Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | 1 |
| Idiopathic Granulomatous Mastitis | 1 |
| B Lymphoblastic Leukemia | 1 |
| Interstitial Lung Disease | 1 |
| Myositis | 1 |
| Rheumatic Fever | 1 |
| Rheumatic Heart Disease in Children | 1 |
| Acute Rheumatic Fever | 1 |
| Rheumatic Heart Disease | 1 |
| Acute Lymphoblastic Lymphoma | 1 |
| Bell Palsy | 1 |
| Hashimoto Thyroiditis | 1 |
| Subacute Thyroiditis | 1 |
| Thyroiditis | 1 |
| Myeloma | 1 |
| Multiple Myeloma | 1 |
| Refractory Multiple Myeloma | 1 |
| Recurrent B Acute Lymphoblastic Leukemia | 1 |
| Adult T Acute Lymphoblastic Leukemia | 1 |
| Ann Arbor Stage II Adult Lymphoblastic Lymphoma | 1 |
| Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | 1 |
| Ann Arbor Stage III Adult Lymphoblastic Lymphoma | 1 |
| Endometrial Endometrioid Adenocarcinoma | 1 |
| Endometrial Hyperplasia | 1 |
| FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | 1 |
| FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | 1 |
| Metastatic Endometrial Endometrioid Adenocarcinoma | 1 |
| Recurrent Endometrial Endometrioid Adenocarcinoma | 1 |
Sponsors
lead sponsor per trial+ 39 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Prednisolone trials
How many clinical trials are testing Prednisolone?
73 current trials in our Canada, Australia, Israel, USA, Germany, Italy, France, China, Spain, Japan, Mexico, Poland, South Korea, Netherlands, Switzerland, Austria, Taiwan, UK, Denmark, Belgium, Sweden, Turkey, Czechia, Brazil, Singapore, Portugal, Ireland, Egypt, Norway and India registers name Prednisolone (also registered as (11beta)-11) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Prednisolone trials recruiting patients?
Yes. 42 of the 73 trials are recruiting: 11 with sites in Canada, 12 with sites in Australia, 12 with sites in Israel, 10 with sites in USA, 10 with sites in Germany, 12 with sites in Italy, 11 with sites in France, 10 with sites in China, 9 with sites in Spain, 10 with sites in Japan, 7 with sites in Mexico, 8 with sites in Poland, 7 with sites in South Korea, 7 with sites in Netherlands, 8 with sites in Switzerland, 6 with sites in Austria, 7 with sites in Taiwan, 6 with sites in UK, 7 with sites in Denmark, 4 with sites in Belgium, 4 with sites in Sweden, 4 with sites in Turkey, 3 with sites in Czechia, 3 with sites in Brazil, 4 with sites in Singapore, 3 with sites in Portugal, 4 with sites in Ireland, 4 with sites in Egypt, 3 with sites in Norway and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Prednisolone clinical trials?
National Cancer Institute (NCI) (7), Merck Sharp & Dohme LLC (5), Post Graduate Institute of Medical Education and Research, Chandigarh (4) and Children's Oncology Group (3), among 54 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Prednisolone clinical trials in Ireland?
Yes. 4 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Is Prednisolone licensed in Ireland?
Yes. The HPRA medicines list includes 10 single-substance products containing Prednisolone, for example DELTACORTRIL ENTERIC 2.5 mg gastro-resistant tablets (Phoenix Labs). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Prednisolone shortage?
The registers we track list 5 entries for Prednisolone: 5 German notices. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Prednisolone works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Prednisolone works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Prednisolone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.